IPSEN – Buy-back programme – Art 5 of MAR – Week 29 – 2026
Aggregated presentation by day and by market
| Weekly report on share repurchases from 13th July to 17th July 2026 | ||||||
| Name of the Issuer | Identify code of the Issuer | Transaction day | Identify code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 13/07/2026 | FR0010259150 | 5 500 | 161,6092 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 14/07/2026 | FR0010259150 | 5 000 | 158,4579 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 15/07/2026 | FR0010259150 | 5 000 | 159,6458 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 16/07/2026 | FR0010259150 | 4 390 | 157,0540 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 17/07/2026 | FR0010259150 | 4 368 | 157,8826 | XPAR |
| TOTAL | 24 258 | 159.0596 | ||||
Attachment

IPSEN – Buy-back programme – Art 5 of MAR – Week 29 – 2026
Aggregated presentation by day and by market
| Weekly report on share repurchases from 13th July to 17th July 2026 | ||||||
| Name of the Issuer | Identify code of the Issuer | Transaction day | Identify code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 13/07/2026 | FR0010259150 | 5 500 | 161,6092 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 14/07/2026 | FR0010259150 | 5 000 | 158,4579 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 15/07/2026 | FR0010259150 | 5 000 | 159,6458 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 16/07/2026 | FR0010259150 | 4 390 | 157,0540 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 17/07/2026 | FR0010259150 | 4 368 | 157,8826 | XPAR |
| TOTAL | 24 258 | 159.0596 | ||||
Attachment

Related stories
Quand les acides biliaires prennent une dimension plus large : comment la biologie de la cholestase transforme la recherche sur les maladies hépatiques rares
Tester l’hypothèse : un pilote ciblé sur l’IA dans le domaine de la santé
Toujours une longueur d’avance : Anne Petit et l’art de concrétiser les médicaments
Related Press Releases
Ipsen – Corrective statement amending the monthly disclosure of the...
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen – June 2026 – Monthly information relative to the...
Ipsen – Half year statement – 2026 06 30
IPSEN – Buy-back programme – Art 5 of MAR –...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus...
Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline
IPSEN – Buy-back programme – Art 5 of MAR –...